<DOC>
	<DOCNO>NCT02418234</DOCNO>
	<brief_summary>The purpose study compare frequency abundance T790M mutation among different Clinical mode EGFR-TKI failure .</brief_summary>
	<brief_title>T790M Mutation ctDNA Patients With NSCLC After EGFR-TKI Failure</brief_title>
	<detailed_description>An observational , non-interventional , multi-central study comparison frequency abundance T790M mutation use amplification refractory mutation system ( ARMS ) digital droplet PCR ( ddPCR ) method among different Clinical mode non-small cell lung cancer ( NSCLC ) patient epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKI ) failure</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirm stage IIIB/IV NSCLC . Investigator confirm progression accord RECIST 1.1 EGFRTKI treatment within 28 day enrollment Activating mutation ( G719A/C/S ; Exon 19 insertion/deletion ; L858R ; L861Q ) EGFR gene least partial response EGFR TKI last â‰¥ 6 month Patient must able comply protocol Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 defined disease progression 28 day previous EGFRTKI treatment . Patient treat investigational agent indication within 4 week study treatment . Histologically confirm small cell lung cancer metastatic tumor Patient histologic cytological diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>circulate tumor DNA</keyword>
	<keyword>T790M</keyword>
	<keyword>amplification refractory mutation system</keyword>
	<keyword>digital droplet PCR</keyword>
</DOC>